

EU DECLARATION OF CONFORMITY  
REGULATION 2017/745

|                                    |                                                                                                           |
|------------------------------------|-----------------------------------------------------------------------------------------------------------|
| <b>MANUFACTURER</b>                | PHARMALINK, S.L                                                                                           |
| <b>ADDRESS</b>                     | AVDA. UNIVERSITAT AUTONOMA, 13<br>PARC TECNOLOGIC DEL VALLES<br>08290 CERDANYOLA DEL VALLES<br>SPAIN      |
| <b>SRN</b>                         | ES-MF-000000144                                                                                           |
| <b>PRODUCT</b>                     | Type ref.: <b>PL0075</b><br>Description: <b>ANTI ALLERGY NASAL SPRAY 20ML</b><br>Trade names: (Annex I)   |
| <b>BASIC UDI-DI</b>                | 843654262TNXZ                                                                                             |
| <b>EMDN CODE</b>                   | Q030103                                                                                                   |
| <b>CLASSIFICATION</b>              | Class IIa (MDR Annex VIII, Rule 5 and Rule 21)                                                            |
| <b>CONFORMITY ASSESSMENT ROUTE</b> | ANNEX XI PART A Regulation 2017/745                                                                       |
| <b>NB</b>                          | 0051 IMQ<br>ISTITUTO ITALIANO DEL MARCHIO DI QUALITÀ S.P.A.<br>Via Quintiliano, 43, 20138 – MILANO, Italy |
| <b>Num.</b>                        | Certificate N: 002/MDR                                                                                    |
| <b>Valid until</b>                 | 2025-12-10                                                                                                |

We herewith declare, under own responsibility, that the medical device covered by the present Declaration is in conformity with Regulation 745/2017 including compliance with related General Safety and Performance Requirements.

**COMMON SPECIFICATIONS**

Common specifications and/or the standards applied for demonstration of the conformity are detailed in Annex II.

Signature

  
  
**PHARMALINK, S.L.**  
 Av. Universitat Autònoma, 13  
 Parc Tecnològic del Vallès  
 08290 Cerdanyola del Vallès  
 Barcelona (Spain)  
 NIF: B-62152335

**Juan Jané**  
**President**

Date

12/12/2022

Type ref.: **PL0075**

Description: **ANTI ALLERGY NASAL SPRAY 20ML**

**ANNEX I: TRADE NAMES**

|                                                                          |
|--------------------------------------------------------------------------|
| <b>FREENOSE</b>                                                          |
| <b>PHYSIOLOGICA</b>                                                      |
| <b>RESPYVITAL</b>                                                        |
| <b>RESPYSANA</b>                                                         |
| <b>PRONARYL</b>                                                          |
| <b>HUMER RHINITE ALLERGIQUE SPRAY/<br/>HUMER Allergic Rhinitis Spray</b> |

Type ref.: **PL0075**

Description: **ANTI ALLERGY NASAL SPRAY 20ML**

**Annex II: COMMON SPECIFICATIONS AND STANDARDS**

|                                 |
|---------------------------------|
| <b>Quality System</b>           |
| UNE-EN ISO 13485:2016           |
| <b>General Safety Standard</b>  |
| UNE-EN ISO 14971:2020           |
| UNE-EN ISO 62366-1:2015/A1:2020 |
| ISO 10993-1:2018                |
| UNE-EN-ISO 10993-12:2013        |
| ISO 15223:2021                  |
| UNE-EN ISO 1041:2009+A1:2014    |